A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
This year’s American Diabetes Association scientific meeting comes with a hefty price — a policy of no photography and limits on social media. That did not go over well on Twitter.
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
Democratic senators want the Justice Department to reveal what it knows about ProPublica’s recent report that HHS Secretary Tom Price’s stock trades were under investigation by former U.S. Attorney Preet Bharara before the Trump administration fired him.
The HHS Secretary bought stock in companies that stood to benefit from legislation he voted for and sponsored as a Georgia congressman.
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
WikiLeaks documents show a cautious speaker who tried to avoid compromises on policy.
Advierten sobre sitios de internet que publicitan tratamientos “curativos” con células madre porque no son terapias aprobadas por la Administración de Drogas y Alimentos de Estados Unidos (FDA).